Aromatase inhibitors for breast cancer

This publication has 79 references indexed in Scilit:

• Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
  The Lancet, 2007
• Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
  British Journal of Cancer, 2006
• Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer
  Breast Cancer Research and Treatment, 2006
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• An open randomised trial of second-line endocrine therapy in advanced breast cancer
  European Journal of Cancer, 2003
• Breast Cancer Management
  PharmacoEconomics, 2003
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• Endocrine-responsive breast cancer and strategies for combating resistance
  Nature Reviews Cancer, 2002
• Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?
  European Journal of Surgical Oncology, 2001
• A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
  European Journal of Cancer, 1996